Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB378 for postherpetic neuralgia (15 mg three times daily)
2004-003913-18Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing SAB378 15 mg t.i.d with Placebo (2 arms). Primary endpoints: Change in pain intensity score on 11-point Numerical Rating Scale and Safety: adverse events, laboratory, ECG, and vital sign abnormalities. Started Apr 2005; status: completed.
02
Drugs
SAB378
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2004-003913-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003913-18.